Anteris Technologies Files S-1/A Amendment

TL;DR

Anteris Tech filed an S-1/A. Looks like they're still pushing for that IPO.

AI Summary

Anteris Technologies Global Corp. filed an S-1/A amendment on December 9, 2024, to its registration statement. The company, incorporated in Delaware, is in the orthopedic, prosthetic & surgical appliances & supplies industry. Its principal executive offices are located in Eagan, Minnesota, with a phone number of 651-493-0606.

Why It Matters

This filing indicates Anteris Technologies Global Corp. is moving forward with its public offering plans, which could lead to increased capital for operations and expansion in the medical device sector.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it represents a company in the process of going public, which inherently carries risks associated with market conditions, regulatory approvals, and business execution.

Key Numbers

• 333-283414 — SEC File Number (Identifies the specific registration statement being amended.)
• 20241209 — Filing Date (The date the amendment was submitted to the SEC.)

Key Players & Entities

• Anteris Technologies Global Corp. (company) — Registrant
• 333-283414 (dollar_amount) — SEC File Number
• 20241209 (dollar_amount) — Filing Date
• Wayne Paterson (person) — Chief Executive Officer
• 651-493-0606 (dollar_amount) — Business Phone Number

FAQ

Key Financial Figures

• $0.0001 — ng of shares of common stock, par value $0.0001 per share ("Common Stock"), of Anteris
• $6.78 — ing an initial public offering price of $6.78 per share, which was the closing price
• $10.54 — f ATL's ordinary shares on the ASX was A$10.54 per ordinary share, equivalent to a pri
• $1.00 — er share, assuming an exchange rate of A$1.00 to $0.6430, the conversion rate for Aus
• $0 — assuming an exchange rate of A$1.00 to $0.6430, the conversion rate for Australia
• $8.1 million — s and commissions payable by us will be $8.1 million and the total proceeds to us, before ex
• $107.3 million — roceeds to us, before expenses, will be $107.3 million. Delivery of the shares of Common Sto
• $1 — is prospectus were made at the rate of A$1 to $0.6828, the noon buying rate on Dec
• $0.6513 — te for Australian dollars was A$1.00 to $0.6513. v TABLE OF CONTENTS PROSPECTUS S

Filing Documents

• tm245520-23_s1a.htm (S-1/A) — 4721KB
• tm245520d25_ex5-1.htm (EX-5.1) — 12KB
• tm245520d25_ex10-5.htm (EX-10.5) — 104KB
• tm245520d25_ex10-28.htm (EX-10.28) — 518KB
• tm245520d25_ex23-1a.htm (EX-23.1(A)) — 2KB
• tm245520d25_ex23-1b.htm (EX-23.1(B)) — 2KB
• tm245520d25_ex-filingfees.htm (EX-FILING FEES) — 25KB
• lg_anteris-4clr.jpg (GRAPHIC) — 11KB
• ph_transcatheter-4c.jpg (GRAPHIC) — 85KB
• ph_ourproducts-4c.jpg (GRAPHIC) — 44KB
• ph_anticalcification-4clr.jpg (GRAPHIC) — 28KB
• ph_comasurdelivery-4clr.jpg (GRAPHIC) — 23KB
• ph_system-4clr.jpg (GRAPHIC) — 70KB
• ph_commissures-4clr.jpg (GRAPHIC) — 133KB
• ph_firstballoon-4clr.jpg (GRAPHIC) — 20KB
• ph_balloonexpanded-4clr.jpg (GRAPHIC) — 20KB
• ph_finallyballoon-4clr.jpg (GRAPHIC) — 54KB
• fc_clinicalresults-4clr.jpg (GRAPHIC) — 108KB
• lc_earlyfeasibility-4clr.jpg (GRAPHIC) — 39KB
• tb_milestones-4c.jpg (GRAPHIC) — 60KB
• tm245520d25_ex5-1img001.jpg (GRAPHIC) — 2KB
• tm245520d25_ex5-1img002.jpg (GRAPHIC) — 1KB
• 0001104659-24-126560.txt ( ) — 6347KB

RISK FACTORS

RISK FACTORS 12 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 48

USE OF PROCEEDS

USE OF PROCEEDS 50 DIVIDEND POLICY 51 CAPITALIZATION 52

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 96 MANAGEMENT 110 DIRECTOR COMPENSATION 116

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 119 CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS 129 PRINCIPAL STOCKHOLDERS 130

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 132 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 136 SHARES ELIGIBLE FOR FUTURE SALE 140

UNDERWRITING

UNDERWRITING 142 LEGAL MATTERS 151 EXPERTS 151 LIMITATION ON INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S LIABILITY 151 WHERE YOU CAN FIND MORE INFORMATION 151 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 We have not, and the underwriters have not, authorized anyone to provide you any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the underwriters take responsibility for, or provide any assurance as to the reliability of, any other information others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of the shares of our Common Stock. Our business, financial condition, results of operations and prospects may have changed since that date. For Investors Outside the United States (the "U.S.") : We have not, and the underwriters have not, done anything that would permit this offering or the possession or distribution of this prospectus or any free writing prospectus in connection with this offering in any jurisdiction where action for that purpose is required, other than in the U.S. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of Common Stock and the distribution of this prospectus and any such free writing prospectus outside the United States. See the section titled " Underwriting ." i TABLE OF CONTENTS BACKGROUND Anteris Technologies

View Full Filing

View this S-1/A filing on SEC EDGAR